OBJECTIVE The aim of this study is to verify in an isolated working heart swine model if the acute administration of trimetazidine to cardioplegia, without pre-treatment improves heart performance. METHODS Eighteen pairs of swine were used in this working heart model, divided into three groups (n = 6) that underwent regional and global ischemia. Each group was selected to a different treatmen...

BACKGROUND There is evidence that trimetazidine, an anti-ischaemic agent with a direct cytoprotective effect on the myocardium, is effective in stable angina. However, it is not clear whether trimetazidine can improve the mechanical efficiency of chronically dysfunctional myocardium, and whether this potentially beneficial effect can translate into improvements in left ventricular function as w...

In 1969, the Servier Laboratoires introduced trimetazidine, 1-(2, 3, 4-trimethoxybenzyl) piperazine dihydrochloride (Vastarel®) as a medicament for angina pectoris (1). This drug is assumed to reveal its remarkable action through decreasing cardiac work and lower ing the oxygen consumption of the heart (2), but other mechanisms of its action yet await ed clarification. Since trimetazidi...

Myocardial metabolic manipulation using drugs such as trimetazidine may offer a new therapeutic approach to the treatment of heart failure.

Trimetazidine is an anti-ischaemic drug used for angina pectoris treatment. Recently, it has been shown that trimetazidine protects against hepatic ischaemia reperfusion injury. Several hypotheses have been proposed to explain the exact hepatoprotective mechanisms but they still remain unclear. This review assesses the possible mechanisms responsible for the increase of the liver’s tolerance ag...

Trimetazidine is a drug that has been used to reduce the damage of reperfusion injury, which is a mechanism of oxidative aggression that occurs in coronary syndromes, angioplasty procedures, as well as in cardiovascular surgeries. Seeking to improve myocardial protection during procedures that involve reperfusion, attention was recently turned to research on cytoprotective drugs which act on se...

Tissue ischaemia is an important factor in the development of several eye diseases. The commonly accepted idea regarding management of ischaemic effects is that a normal blood flow should be increased. Trimetazidine, an anti-ischaemic agent, can have a positive effect on retinal disorders with an ischaemic component. Trimetazidine seems to have an influence on selected visual parameters (improv...

The heart is capable of using fatty acids and glucose as its main sources of energy, with their balance depending on many physiological and pathological situations. In the presence of ischemia, there is a switch to oxidation of fatty acids, which has deleterious effects on the function of the heart. Trimetazidine reduces fatty acid oxidation and increases glucose oxidation, which tends to norma...

Trimetazidine dihydrochloride, a cellular antiischemic agent indicated in the management and prophylaxis of angina pectoris is given as 20 mg thrice daily in the conventional dosage regimen. The purpose of the present study was to formulate and evaluate twice a day extended release tablets containing 30 mg trimetazidine dihydrochloride. The method developed to formulate these extended release t...

Alterations in cardiac metabolism are present in ischemic heart disease and heart failure, suggesting an increased utilization of non carbohydrate substrates for energy production, with a reduction in the efficiency of myocardial oxygen consumption and ischemia-reperfusion damage. A direct approach to the manipulation of cardiac energy metabolism consists in modifying substrate utilization. Tri...